Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886986 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04886986 is a Phase 1 study that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 42 participants.
The verdict
NCT04886986, a Phase 1 study, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). This phase of the study (phase I) will determine the highest dose of the study intervention that can be safely given.
Interventions
- DRUG 68Ga-PSMA-11
- DRUG 177Lu-PSMA-617
- DRUG 225Ac-J591
- DRUG 177Lu-PSMA-I&T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04886986
The ClinicalTrials.gov registry entry for NCT04886986 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 68Ga-PSMA-11 is the first listed.
NCT04886986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04886986 about?
NCT04886986 is a clinical study titled "Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer". This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells)...
What is the current status of trial NCT04886986?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-06-30. Estimated completion is 2029-12.
What interventions are being tested in trial NCT04886986?
The interventions under investigation include: 68Ga-PSMA-11 (DRUG), 177Lu-PSMA-617 (DRUG), 225Ac-J591 (DRUG), 177Lu-PSMA-I&T (DRUG).
Who is sponsoring clinical trial NCT04886986?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.